A Phase 1 clinical trial in the U.K. is recruiting patients with mild to moderate Parkinson’s to assess MODAG Neuroscience Solutions‘ investigational oral therapy anle138b, which seeks to slow or halt disease progression.
The trial (NCT04685265) will be conducted at a single site at Nottingham University Hospital, in central England, according to a press release from Cure Parkinson’s. Researchers are looking to enroll 24 adults, ages 50 to 80, who are able to walk unaided.
More information on enrollment is available here, as well as by email. Patients in the U.K. may get additional information via telephone, by calling 03303 031 000.
“Anle138b is taken by mouth, easily enters the brain, and preclinical research indicates that it is very good at reducing levels of aggregated [clumped] alpha synuclein [protein] inside cells. The reduction of alpha-synuclein in the brain has been reported to reverse Parkinson’s-like motor symptoms in animal models,” Cure Parkinson’s says on its website.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Another Study Finds A Link Between Covid-19 and Parkinson's Disease 
New and current hope for Parkinson's Disease
Free Webinar: “Zhittya's Parkinson's Disease Research Study: 6-Month Patient Follow-Up Report”
